Welcome to our dedicated page for TruBridge SEC filings (Ticker: TBRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TruBridge, Inc. (NASDAQ: TBRG) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, drawn in real time from the EDGAR system and supported by AI-powered analysis. TruBridge is a healthcare technology and solutions company focused on rural and community hospitals and providers, and its filings offer detailed insight into how it reports financial performance, manages risk, and governs its operations.
Key documents for TruBridge include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company presents audited and interim financial statements, segment information for its Financial Health and Patient Care business units, and discussions of risk factors and internal control over financial reporting. For example, TruBridge has disclosed material weaknesses related to revenue processes and customer contract changes in prior years, and it has reported on changes to its independent registered public accounting firm, including the dismissal of Grant Thornton LLP and engagement of KPMG LLP.
Current reports on Form 8-K capture material events such as quarterly earnings releases, leadership changes, board refreshment actions, cooperation agreements with major shareholders, and financing developments like the 2025 Amended and Restated Credit Agreement with its lending partners. These filings help investors understand how TruBridge is addressing governance, capital structure, and strategic priorities in the context of rural and community healthcare.
On this page, users can review TruBridge’s Forms 10-K and 10-Q, 8-Ks describing significant corporate events, and other exhibits referenced in those reports. AI-generated summaries highlight the main points of each filing, explain complex accounting or control matters in plain language, and surface items related to revenue cycle management, EHR and patient engagement operations, internal control conclusions, and auditor changes. Filings related to executive and director arrangements, such as severance agreements and board appointments, are also accessible, along with any associated exhibits.
By using these tools, readers can quickly understand what TruBridge reports to regulators about its financial health, operational segments, governance, and risk profile, without having to parse every line of the underlying documents themselves.
TruBridge, Inc. director Andris Upitis reported dispositions of common stock in connection with a merger that took the company private. On the merger’s effective time, each outstanding share of TruBridge common stock was cancelled and converted into the right to receive $26.25 per share in cash. This included shares held indirectly through Ocho Investments, LLC and shares held directly, leaving no TruBridge shares reported as owned after the transaction.
TruBridge, Inc. director Amy K. O'Keefe reported a disposition of 7,561 shares of common stock on July 9, 2026, recorded as a disposition to the issuer. This occurred in connection with the closing of a Merger under an Agreement and Plan of Merger, where Merger Sub merged into TruBridge, leaving TruBridge as a wholly owned subsidiary of Parent. At the effective time of the Merger, each outstanding share of TruBridge common stock was cancelled and converted into the right to receive $26.25 per share in cash, and O'Keefe’s reported direct holdings became 0 shares following the transaction.
TruBridge, Inc. director Christopher T. Hjelm reported a disposition of common stock tied to the company’s cash merger. On July 9, 2026, all of his 31,591 shares of TruBridge common stock were disposed of to the issuer in connection with the closing of a merger under the April 23, 2026 Merger Agreement. At the effective time of the merger, each outstanding share of TruBridge common stock was cancelled and converted into the right to receive $26.25 per share in cash; following this transaction, Hjelm reported holding no TruBridge common shares.
TruBridge, Inc. director David A. Dye reported dispositions of all his common stock holdings in connection with the cash merger completed on July 9, 2026. At the merger’s effective time, each share of TruBridge common stock was cancelled and converted into the right to receive $26.25 per share in cash, including shares held directly and in a trust for the benefit of the reporting person and his children. Earlier, in March 2025, a total of 4,783 shares had been withheld to cover taxes upon the vesting of restricted stock.
TruBridge, Inc. director Glenn Tobin reported a disposition of 50,687 shares of common stock on July 9, 2026, shown as a Disposition to issuer. This occurred in connection with a merger in which a subsidiary of Inventurus Knowledge Solutions, Inc. merged into TruBridge. At the merger’s effective time, each outstanding TruBridge common share was cancelled and converted into the right to receive $26.25 per share in cash, without interest and subject to applicable withholding taxes.
TruBridge, Inc. Controller MacIntyre Vita reported issuer-related dispositions of common stock tied to the closing of a merger. A portion of unvested restricted stock was forfeited at the merger’s effective time, and remaining common shares were cancelled and converted into the right to receive $26.25 per share in cash. Following these transactions, Vita reported holding 0 shares of TruBridge common stock.
TruBridge, Inc. Chief Business Officer Michael Daughton reported two issuer dispositions of common stock tied to the closing of a merger on July 9, 2026. A total of 8,749 shares of his unvested restricted stock was forfeited at the merger’s effective time under the merger agreement. The remaining 59,315 shares of common stock were cancelled and converted into the right to receive $26.25 per share in cash as merger consideration, after which he held no TruBridge common shares.
TruBridge, Inc. General Manager Patient Care, David Harse, reported dispositions of common stock in connection with the closing of a merger in which TruBridge became a wholly owned subsidiary of Inventurus Knowledge Solutions, Inc. At the merger’s effective time, his outstanding common shares were converted into the right to receive $26.25 per share in cash, while a portion of his unvested restricted stock was forfeited under the merger agreement.
TruBridge, Inc. completed a merger in which its common stock was cancelled and converted into the right to receive $26.25 per share in cash, subject to withholding taxes. General Counsel Kevin Plessner disposed of 12,460 shares of common stock to the issuer at $26.25 per share, and 2,150 unvested restricted shares were forfeited at the merger’s effective time. Following these transactions, he no longer holds TruBridge common stock.
TruBridge, Inc. executive Wilson Merideth, Financial Health GM, reported two dispositions of common stock in connection with the closing of a cash merger. On July 9, 2026, pursuant to a Merger Agreement under which TruBridge became a wholly owned subsidiary of Inventurus Knowledge Solutions, each share of TruBridge common stock was cancelled and converted into the right to receive $26.25 per share in cash. Merideth disposed of 7,734 shares at $26.25 per share in an issuer disposition, and a further 4,308 unvested restricted shares were forfeited at the merger’s effective time under the Merger Agreement.